COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,804 Articles (22,527 medRxiv, 8,277 bioRxiv)

Most recent first Previous |  Page 2365: Articles 23641-23650  | Next

Ad26-vector based COVID-19 vaccine encoding a prefusion stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses
Bos, R., Rutten, L., van der Lubbe, J. E. M., Bakkers, M. J. G., Hardenberg, G., Wegmann, F., Zuijdgeest, D., de Wilde, A. H., Koornneef, A., Verwilligen, A., van Manen, D., Kwaks, T., Vogels, R., Dalebout, T. J., Myeni, S. K., Kikkert, M., Snijder, E. J., Li, Z., Barouch, D. H., Jort, V., Langedijk, J. P., Zahn, R. C., Custers, J., Schuitemaker, H.
10.1101/2020.07.30.227470 — Posted: 2020-07-30
A dynamic regulatory interface on SARS-CoV-2 RNA polymerase
Shi, W., Chen, M., Yang, Y., Zhou, W., Chen, S., Hu, Y., Liu, B.
10.1101/2020.07.30.229187 — Posted: 2020-07-30
Substrate specificity of SARS-CoV-2 nsp10-nsp16 methyltransferase
Benoni, R., Krafcikova, P., Baranowski, M., Kowalska, J., Boura, E., Cahova, H.
10.1101/2020.07.30.228478 — Posted: 2020-07-30
Immuno-informatics Design of a Multimeric Epitope Peptide Based Vaccine Targeting SARS-CoV-2 Spike Glycoprotein
Chukwudozie, O. S., Gray, C. M., Fagbayi, T. A., Chukwuanukwu, R. C., Oyebanji, V. O., Bankole, T. T., Adewole, R. A., Eze, D. M.
10.1101/2020.07.30.228221 — Posted: 2020-07-30
EUAdb: a resource for COVID-19 test development
Woronik, A., Shaffer, H. W., Kiontke, K., Laurent, J. M., Zambrano, R., Boeke, J. D., Fitch, D. H. A.
10.1101/2020.07.30.228890 — Posted: 2020-07-30
Mucin-type O-glycosylation Landscapes of SARS-CoV-2 Spike Proteins
Zhang, Y., Zhao, W., Mao, Y., Chen, Y., Hu, L., Zhu, J., Gong, M., Cheng, J., Yang, H.
10.1101/2020.07.29.227785 — Posted: 2020-07-30
SARS-CoV-2 Spike Protein Interacts with Multiple Innate Immune Receptors
Gao, C., Zeng, J., Jia, N., Stavenhagen, K., Matsumoto, Y., Zhang, H., Li, J., Hume, A. J., Muehlberger, E., van Die, I., Kwan, J., Tantisira, K., Emili, A., Cummings, R. D.
10.1101/2020.07.29.227462 — Posted: 2020-07-30 Discussion: Onsite | Offsite
No SARS-CoV-2 cross-neutralization by intravenous immunoglobulins produced from plasma collected before the 2020 pandemic
Schwaiger, J., Karbiener, M., Aberham, C., Farcet, M. R., Kreil, T. R.
10.1101/2020.07.30.228213 — Posted: 2020-07-30
A Next Generation Bivalent Human Ad5 COVID-19 Vaccine Delivering Both Spike and Nucleocapsid Antigens Elicits Th1 Dominant CD4+, CD8+ T-cell and Neutralizing Antibody Responses
Rice, A., Verma, M., Shin, A., Zakin, L., Sieling, P., Tanaka, S., Adisetiyo, H., Taft, J., Patel, R. S., Buta, S., Martin-Fernandez, M., Morimoto, B., Gabitzsch, E., Safrit, J. T., Balint, J., Dinkins, K., Spilman, P., Bogunovic, D., Rabizadeh, S., Niazi, K., Soon-Shiong, P.
10.1101/2020.07.29.227595 — Posted: 2020-07-30 Discussion: Onsite | Offsite
Use of a humanized anti-CD6 monoclonal antibody (itolizumab) in elderly patients with moderate COVID-19
Ramos-Suzarte, M., Diaz, Y., Martin, Y., Calderon, N. A., Santiago, W., Vinet, O., La O, Y., Perez, J., Oyarzabal, A., Perez, Y., Lorenzo, G., Cepeda, M., Saavedra, D., Mazorra, Z., Estevez, D., Lorenzo-Luaces, P., Valenzuela, C., Caballero, A., leon, K., Crombet, T., Hidalgo, C. J.
10.1101/2020.07.24.20153833 — Posted: 2020-07-30

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).